This suggests that GLP-1 agonists do not have a direct effect on lipid metabolism in NAFLD and that the lipid changes reported in the literature may have been indirectly due to associated weight loss through the satiety effects of the GLP-1 agonists such as liraglutide [17]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.